Pain and substance misuse: improving the patient experience. by unknown
Pain and substance misuse: 
improving the patient experience
A consensus statement prepared by The British Pain Society in collaboration with 
The Royal College of Psychiatrists, The Royal College of General Practitioners 
and The Advisory Council on the Misuse of Drugs
April 2007
To be reviewed April 2010
Copyright: The British Pain Society 2007
ii
Published by:
The British Pain Society
Third Floor - Churchill House 
35 Red Lion Square - London WC1R 4SG
Website: www.britishpainsociety.org
ISBN: 978-0-9551546-5-2
iii
Pain and substance misuse: 
improving the patient experience 
A consensus statement prepared by The British Pain Society in collaboration with The Royal 
College of Psychiatrists, The Royal College of General Practitioners and The Advisory Council on 
the Misuse of Drugs
 
Introduction
This document aims to identify elements of good practice in the management of pain and in the 
prescription of opioid drugs. It provides non-specialists with appropriate information to assess 
the needs of and manage pain in patients who are or have previously been substance misusers. 
The document also gives guidance on models of collaborative working among relevant healthcare 
professionals involved in the care of patients with pain who are using, or are at risk of using, 
drugs inappropriately. It therefore aims to improve practice in managing this group of patients with 
complex needs.
The document particularly addresses the dual challenges of safe use of opioids for long term pain 
control and the effective management of persisting pain symptoms in the addicted patient. The 
group recognizes that substance misusing patients will frequently present to hospital for surgery 
or following trauma. These individuals will need short term pain management in this acute setting 
and many hospitals have protocols to guide professionals in these circumstances. Key elements 
of good practice in acute pain management in this population are outlined in section 5.
A cohesive plan for the management of pain has the patient at its centre. Treatment of pain should 
not impose additional burdens for the patient. Mutual understanding of the type of problems 
which may develop, and an agreed plan of how such problems may be managed, improves 
the patient’s experience of treatment. Similarly, if concerns are discussed openly with patients 
misusing prescribed or illicit substances, it is possible to provide effective management of pain 
safely. 
Persistent pain is common and disabling. Treatment with opioid medication will be appropriate for 
a significant proportion of patients. Professionals caring for these patients need to be aware that 
these drugs may be used inappropriately and should be able to identify and manage problems if 
they arise. Patients with pain and a past or current history of substance misuse pose particular 
challenges when prescribing analgesics. Lack of understanding of relevant pharmacology 
and concern regarding potential for misuse of prescribed medication can result in pain being 
inadequately managed in substance misusers. 
This document does not attempt to provide prescriptive guidelines for the management 
of particular presentations, but accepts that pain needs individualised management. The 
document considers the epidemiology of pain and of substance misuse, relevant neurobiology 
and pharmacology as well as definitions, legal requirements and therapeutic interventions to 
inform clinicians and improve practice. It is not within the scope of this document to discuss all 
substances of misuse. The focus is on commonly misused substances and those with specific 
relevance to the management of pain. The document examines the issues as they relate to 
both acute and chronic pain as well as special populations, as each requires different clinical 
management. 
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The document is accompanied by an information leaflet supporting patients at risk of substance 
misuse in making informed treatment choices about pain management.  It helps them and 
their carers recognise problems that may occur and explains what sort of information needs 
to be given to professionals from whom they are seeking help, to support a safe and effective 
management plan.
Methods
These recommendations have been prepared by a consensus group of professionals from the 
fields of pain management and substance misuse. Additional contributions have been made by 
experts from other relevant disciplines. Research evidence is referenced, where such evidence is 
available, however the lack of research evidence available to inform this topic is noteworthy.  A 
provisional version of this publication was launched in April 2006.  This was circulated to relevant 
stakeholder individuals and organisations for consultation.  Feedback from this consultation has 
been incorporated by the consensus group into this final version of the document.  In accordance 
with British Pain Society publications strategy, the document will be revised and updated in 2010.
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2Executive Summary
• Both persistent pain and substance misuse are common in the general population. In addition, 
substance misusing individuals have additional health and social problems which place them at 
high risk from conditions that may require management of pain.
• Both pain and addiction are complex neurobiological phenomena with significant affective 
and cognitive as well as social and environmental influences on the perceived experience and 
clinical presentation.
• The terms tolerance, dependence and addiction have been variously defined and must be 
clearly understood not only in the context of substance misuse but also when prescribing 
controlled drugs for pain management.
• An understanding of the pharmacology of commonly misused substances and treatments for 
addiction underpins effective management of pain in a substance misusing patient.
• A legal framework exists for the control and regulation of drugs that are considered dangerous 
or otherwise harmful. Many analgesic medications are controlled within this framework.
• Pain, both acute and chronic, is a complex sensory and emotional experience shaped not 
only by biological but also psychological social and cultural factors and it should be evaluated 
in this context. Additionally, persisting pain has a number of predictable psychosocial 
consequences which will need support and management.
• Opioids have been shown in clinical trials to provide effective analgesia in a number of pain 
conditions. The primary purpose of prescribing opioids is for pain relief but complete relief 
of symptoms is rarely achievable: an acceptable balance between useful reduction in pain 
intensity and side effects is the goal.
• Effective opioid therapy may be complicated by development of a hyperalgesic state.
• The prescription of opioids may result in problem drug use. The likelihood of this occurring may 
be influenced by a number of social, psychological and health related factors.
• Controlled drugs prescribed for pain may be diverted. Prescribers must be aware of this risk.
• The possibility of substance misuse must be discussed with a patient when prescribing 
opioids. If concerns arise, they must be explored sensitively and steps taken to minimise the 
risk of inappropriate medication use.
• Addiction is a complex phenomenon which can be adequately conceptualised only if 
biological, psychological and social aspects are considered. Labels and preconceptions neither 
explain behaviour, nor give useful ways to address it, and are therefore unhelpful. 
• Patients with a history of substance misuse may have had poor previous experiences of 
interaction with healthcare professionals. Trust is required from both clinicians and patients.
• Comprehensive assessment of both pain and substance misuse (including alcohol), is 
mandatory when managing pain in the addicted patient.
• There are a number of reasons why individuals who are drug dependent may have greater than 
expected needs regarding pain management.
• Management of pain in the patient recovering from addiction presents specific challenges. 
Management of anxiety is key, as relapse may be precipitated by both anxiety and pain. The 
management of acute pain in these patients needs to include a clear plan for appropriate 
cessation of therapy and a plan for appropriate support following discharge from hospital.
• Relationships between primary care, specialist pain management services and addiction 
medicine services need to be clearly defined to support effective management of patients with 
a history of substance misuse and safe prescription of controlled drugs for pain.
3• Patients with a history of substance misuse who need palliative care services should not 
be denied opioids, when appropriate, to manage their pain. These will need to be given in 
addition to any drugs they are receiving as substitution therapy. Withdrawal symptoms need 
to be recognised and managed, particularly when patients are admitted to an inpatient facility. 
Collaboration with specialist drug services is important when planning discharge and ongoing 
treatment.
• Pregnant patients receiving opioid substitution therapy will need appropriate analgesia in labour 
in addition to their opioid maintenance drugs.
• The prevalence of substance misuse and of painful disorders is high in the prison population. 
Management of this group must be of comparable standard to that provided in the community. 
Poor sleep, anxiety and distress can exacerbate the experience of pain. Diversion of prescribed 
opioids is a significant problem. Supervised medication consumption may be difficult in 
the absence of 24 hour medical care. The use of modified release oral preparations has 
advantages in this population.
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1.1 Epidemiology of pain and of substance misuse
Persistent pain affects around one in seven of the UK population i.e. 13%. This equates 
to about five million adults in the UK. Generally, pain becomes more prevalent as the 
population ages, although the prevalence of pain in those under 40 years of age is about 
17%. Persistent pain is, by definition, long-standing, with sufferers having had pain on 
average for six years. The most common causes of persistent pain are back pain, arthritis 
and headache. Persistent pain is frustrating and distressing and can impair function in a 
number of domains. 
The prevalence of drug misuse in Britain is difficult to assess. A British household survey 
in 2000 reported that 7% of 16 to 74 year olds were dependent on alcohol. In the same 
survey, 2% of the population was dependent on cannabis alone and a further 1% on other 
drugs with or without cannabis. The prevalence of alcohol misuse is high. The British 
Household survey showed that 19% of the population had used alcohol at hazardous 
amounts on occasions. The British Crime Survey indicates that in 2000, around one-third 
of those aged 15 to 59 had taken illegal drugs at some time in their lives, with 11% using 
in the past year and 6% describing themselves as regular users. The most frequently used 
drug is cannabis, with only one per cent of the population reporting the use of heroin and 
crack-cocaine. Only a minority of those who try drugs will develop problems and require 
drug treatment but it is particularly the opioid misusing population that poses challenges to 
the adequate and appropriate management of pain. 
Deprivation and social exclusion are likely to make a significant contribution to the causes, 
complications and intractability of drug misuse. Deprivation relates statistically to the types 
and intensities of drug misuse that are problematic. Similarly, poor housing, or lack of 
access to affordable housing, is another contributory factor in drug misuse. Other important 
factors include educational disadvantage, criminal involvement, unemployment and low 
income.
Drug misuse has been called a chronic relapsing condition. While many drug misusers do 
successfully recover from drug addiction, most make several attempts to do so, lapsing or 
relapsing into drug misuse in intervening periods. 
Drug misusers present with a myriad of other health and social problems, particularly in 
relation to physical and psychiatric co-morbidity and social care needs. Drug misusers 
may present with physical health, mental health, social, and criminal problems all of which 
must be addressed for effective management. Drug users are more likely to suffer from 
accidental and non accidental injury, and medical complications related to their drug use. 
This places them at high risk from physical problems that may require analgesia. 
61.2 Neurobiology of pain and addiction
1.2.1 Neurobiology of pain
Pain has been defined as “An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” (International Association for the Study of Pain 1996). It is clear from this 
definition that pain can be regarded as more than a simple sensory perception and 
that it has affective and cognitive components. From a neuro-behavioural perspective 
pain ranks alongside thirst, hunger, fatigue and sexual desire as a motivational driver 
for a change in behaviour.
Acute pain is an expected consequence of tissue injury, is usually self limiting 
and is relatively easy to treat. In contrast chronic pain is more complex. There is 
often a mismatch between the subjective report of symptoms and clear causative 
pathology. In the case of neuropathic pain (caused by damage to or dysfunction of 
nervous tissue) the pain signals are generated within the nervous system itself. The 
neurobiological complexity of the perceived pain experience is being increasingly 
elucidated by functional imaging studies. The cortical pain matrix describes brain 
regions that receive inputs from the thalamus and that are involved in the cognitive 
recognition of pain and the co-ordination of associated behavioural and autonomic 
responses. These regions include primary and secondary somatosensory, insula and 
anterior cingulate cortices. In vertebrates this is not a one way sensory recognition 
system but rather the organism can choose to attend to a noxious input or disregard 
it if other behavioural drives are conflicting. As a result the perception of pain (and 
consequent behavioural response) is not directly related to the magnitude of the 
inciting stimulus. The degree to which the central nervous system itself contributes 
to the perpetuation of chronic pain is the subject of increasing study. In particular the 
role of descending influences, both excitatory and inhibitory on injury signals in the 
spinal cord is being defined. It is by means of these descending pathways that the 
brain can modulate the pain experience. 
1.2.2 Neurobiology of addiction
Misused drugs affect the neurochemistry of reward pathways in the brain. This is 
axiomatic for if they did not they would not be misused. Social and environmental 
factors play a large part in the vulnerability to and consequences of drug misuse 
but the acute and enduring effects of the drugs on neurochemistry are the most 
important mechanism of action.
One core theory of addiction is that misused drugs are able to ‘hijack’ natural drive 
and motivational systems. The ascending dopamine pathway from the brainstem 
ventral tegmental area, projecting up through the nucleus accumbens and thence 
to the frontal cortex is pivotal in this process. Specifically all “addictive” drugs are 
able to stimulate dopamine release in the nucleus accumbens in animal models. 
Demonstrating this in humans has been more problematic. To date, neuroimaging 
studies have shown this effect for stimulants and alcohol, but not yet for opioids. This 
dopamine pathway appears to signal the presence of stimuli that predict important 
events, such as the arrival of drug in the brain. The net result is that drug related 
stimuli are more attentionally demanding and non-drug related stimuli become less 
important; abstinence is difficult to achieve and harder to maintain. A general down-
regulation of dopamine function is thought to underlie the key features of anhedonia 
and craving in early abstinence from opioids, stimulants, nicotine and alcohol.
7Addiction involves multiple other neurotransmitter systems. The endogenous opioid 
system is directly affected by opioid drugs, but there is increasing evidence of 
its involvement in the effects of cannabis, cocaine and alcohol. Many drugs also 
provoke a surge of noradrenaline in early abstinence. This may be the cause of the 
insomnia that is such a common feature and frequent cause of relapse. Serotonin 
systems may play a part in some of the mood consequences of drug misuse. 
Basal serotonin function is also thought to affect impulsivity and possibly the risk of 
developing drug misuse problems.
1.3 Substance misuse: terminology
The terms tolerance, dependence and addiction have been variously defined and have 
been developed in the context of drug use in those without pain. Patients, carers, and 
health care professionals can confuse these terms and misunderstanding can lead to 
reluctance both in prescribing analgesia and adhering to treatment with controlled drugs. 
The following pragmatic definitions aim to distinguish between expected physiological 
consequences of drug administration and the more complex syndrome of addiction.
Tolerance
Tolerance is a pharmacological phenomenon whereby identical doses of a drug 
induce decreasing levels of effect. Alternatively, higher doses are required to produce 
the same level of effect. The time-scale of this process varies considerably. Some 
drugs are able to induce rapid and transient tolerance over a matter of hours; others 
require prolonged periods of consistent use. Tolerance may occur to both the desired 
effect of a drug and to its unwanted effects.
Tolerance can occur as the result of many processes. Pharmacological tolerance can 
be the result of, for example, a decrease in the number of opioid binding sites, acute 
depletion of the neurotransmitter released by the drug, or by decreased activity in 
intra-cellular second messenger systems. Behavioural tolerance is also described, 
where the drug evokes an equivalent pharmacological response, but the individual 
learns over time how to compensate for the effects of the drug. Tolerance may vary 
with time and setting. It has been shown that in habitual users of a drug, the body 
produces homeostatic mechanisms to partially counteract the effects of drugs. 
These processes are induced by stimuli that predict drug availability. This means that 
doses of drug that have previously been safely used can result in lethal overdose 
if taken in unfamiliar circumstances. This is referred to as “context-dependent 
tolerance”.
Withdrawal
Withdrawal is a syndrome resulting from cessation of, or reduction in, heavy and 
prolonged substance use (Diagnostic and Statistical Manual of Mental Disorders - 
Fourth Edition DSM-IV). It is often divided into psychological phenomena e.g. craving, 
anhedonia and agitation and physical phenomena such as diarrhoea or tachycardia. 
The distinction between the two terms is somewhat arbitrary as physical withdrawal 
always has a psychological component. Physiological withdrawal symptoms are 
often used to diagnose the presence, or absence, of dependence as distinct to 
the syndrome of addiction. Withdrawal can also manifest when pharmacological 
antagonists e.g. naloxone are administered to someone dependent on heroin or 
other opioids. 
8Addiction
Addiction is a syndrome and pattern of substance misuse. There is more than one 
set of diagnostic criteria, but most are based on the six key elements of: 
salience drug and related stimuli become increasingly important
conflict intra-psychic, loss of control over use of the substance
tolerance as above
withdrawal as above
relapse rapid reinstatement of dependent use after a period of 
abstinence
mood modification the substance may induce a pleasant positive effect or 
remove a negative mood state
Both International Classification of Diseases, Tenth Revision (ICD-10) and DSM-IV 
definitions have diagnostic criteria based on these elements as well as inclusion of an 
item on continued substance use in the face of harm caused by its use. Diagnosis 
requires three symptoms from the list to have occurred at the same time in the past 
12 months. Neither set of criteria requires that the substance modify mood, merely 
that it is psychoactive. 
Pseudoaddiction
The term pseudoaddiction has been coined to describe behaviours such as drug 
hoarding, attempts to obtain extra supplies, and requests for early prescription or 
increased dose, in patients whose pain is undertreated. In such circumstances 
patients may resort to illicit drug use. These behaviours may be mistaken as signs of 
addiction, but are an attempt to obtain better pain relief. When pain is relieved these 
behaviours cease.
Dependence
The confusion in terminology between addiction and dependence has caused 
misunderstanding in the profession as well as the lay public. Clinicians are often 
confronted by patients reluctant to take medications that may cause physical 
dependence because this has been confused with addiction. 
Dependence on a substance describes the state of requiring the substance to 
prevent physiological withdrawal. Addiction describes continued drug use despite 
harm as described above. Dependence may occur in the context of addiction, but 
can also occur in the non-addicted patient. Physical dependence may also occur 
following long-term use of a number of drug classes not associated with misuse 
and addiction including beta blockers, corticosteroids and alpha-2-adrenoceptor 
agonists.
Problem analgesic use 
Problem analgesic use may be described by reference to the patient’s thoughts 
around, and pattern of use of, analgesic substances rather than the quantity used. 
Where analgesics are being used to regulate affect, rather than control pain this 
may indicate a problem or developing potential problem. Evidence of craving, 
increased salience, or other components of addiction are also likely to be indicative 
9of problems.  The cognitions of the patient regarding their drug use are crucial to an 
understanding of potential problems and these need to be explored with the patient. 
For example, the patient may be using the medication to remove fear of pain, or 
unhappiness caused by pain, rather than for pain reduction.
1.4 Pharmacology of substance misuse
1.4.1 Useful definitions (see figure 1)
Agonist
An agonist drug binds to its receptor and fully stimulates the system in a dose-
dependent manner.  When all receptors are occupied the system is maximally 
stimulated.
Partial agonist
A partial agonist will bind to its site of action and stimulate the system in a dose 
dependent manner.  It will have a lesser effect than a full agonist, so that when all 
receptors are occupied the system is not maximally stimulated. Partial agonists can 
act as antagonists in the presence of a competing full agonist (this is the case, for 
example with the partial agonist, buprenorphine which can precipitate withdrawal in 
the presence of a full agonist such as diamorphine). 
Antagonist
An antagonist binds to its receptor and blocks it from being stimulated. If the system 
is in an unstimulated state, then this may have no noticeable effect, but if the system 
is being stimulated by an agonist then this is likely to be displaced and an antagonist 
effect is produced.
In most cases the level of affinity for a receptor is greatest for an antagonist, followed 
by a partial agonist, then an agonist. However, this is usually a competitive effect, 
therefore the blockade produced by an antagonist can sometimes be overcome by 
large doses of agonist.
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Fig 1. A comparison of agonism, antagonism and partial agonism 
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1.4.2 Pharmacology of specific drugs
A full description of the pharmacology of all drugs with misuse potential is beyond 
the scope of this document. The drugs described below are selected because 
they are common, have important implications for persistent pain and its treatment, 
or both. It is increasingly common to encounter polydrug use and this should be 
considered when taking a drug history. 
Opioids
The term opioid describes all substances active at the opioid receptor: synthetic, 
endogenous or exogenous. All misused opioids are agonists at the mu opioid 
receptor. Many are also agonists at the kappa and delta opioid receptors. Exceptions 
include buprenorphine, nalbuphine and pentazocine. Buprenorphine is a partial 
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agonist at the mu receptor and antagonist at the kappa receptor. Nalbuphine and 
pentazocine are both kappa agonists and mu antagonists, although this is only a 
weak effect of pentazocine. Mu opioid agonists have indirect effects that increase 
dopamine release in the meso-cortico-limbic system and suppress noradrenaline 
secretion in the locus coeruleus. The subjective effects of opioids are described as a 
feeling of calm and relaxation with a sense of being removed from ones environment 
and free from distress. Care should be taken when prescribing buprenorphine or 
nalbuphine to patients already opioid dependent as both may provoke acute opioid 
withdrawal.
All opioid medicines are potentially subject to misuse. In addition to drugs such as 
pethidine and morphine, misuse may occur with many other preparations including 
tramadol, buprenorphine, codeine, and dihydrocodeine. Nalbuphine is an injectable 
opioid that has gained particular popularity amongst bodybuilders who use it to 
reduce the pain associated with weight training.
The classic symptoms of shivering, goosebumps and runny nose that make up the 
“cold turkey” of opioid withdrawal are a direct result of the release of chronic opioid 
suppression of the noradrenaline system. A surge of noradrenaline is released into 
a supersensitive system causing what is often termed the “noradrenergic storm” of 
withdrawal.
Cocaine
Cocaine, and crack (the free amide base of the cocaine salt), are inhibitors of the 
dopamine reuptake pump. They have similar, but lesser, effects on noradrenaline and 
serotonin reuptake and also block sodium channels. Cocaine and crack differ only 
in their pharmacokinetics. Subjectively, users describe elation, increased energy and 
confidence. Withdrawal is characterised by depression, anxiety, malaise, dysphoria, 
insomnia and craving.
Amfetamine and derivatives
Amfetamine differs from cocaine in that as well as acting as a reuptake inhibitor it 
directly stimulates the release of dopamine from the presynaptic neurone. The effects 
of amfetamine are described as similar to cocaine. 
The withdrawal syndrome is characterised by depression, anergia, agitation, irritability 
and craving. There is a small but significant risk of serious depression with suicidality 
developing some days later.
Amfetamine analogues, like MDMA (‘ecstasy’), have very similar patterns of actions 
with differing relative effects on dopamine, noradrenaline or serotonin neurones. 
Ecstasy has particularly dominant serotonergic effects. While the effects of 
amfetamine are described as similar to, but harsher than, cocaine, MDMA evokes 
feelings of heightened warmth and empathy to others and greater awareness of 
social surroundings.
Ketamine
Ketamine has enjoyed increasing popularity as a drug of misuse. Its effects 
as a dissociative anaesthetic are related to its ability to induce altered states 
of consciousness, often referred to as the “K-hole”. Users describe this as an 
experience of altered reality or deeper understanding. As far as is currently known, 
the main pharmacological effect is antagonism of glutamate at the NMDA receptor. 
There is also evidence of some effect in the dopamine, noradrenaline and serotonin 
12
systems. Dependence has been described occasionally and there are reports 
of compulsive use, tolerance and drug seeking behaviour but no documented 
withdrawal syndrome. The adverse cardiovascular and psychotomimetic effects of 
the drug and the propensity to induce psychotic relapse or induce schizophrenia in 
susceptible individuals has led to the recent control of Ketamine under the Misuse of 
Drugs Act 1971.
Ketamine is known to have analgesic properties but the evidence for its use in the 
management of persistent pain remains speculative.
Cannabis
Cannabis is widely used.  Most users are “recreational”, but surveys also reveal 
that about 10-20% of patients attending pain clinics self administer illegally 
obtained cannabis for symptom relief. As a plant compound, cannabis has a rich 
pharmacology with multiple psychoactive ingredients; the two most important being 
delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol. The exact composition 
of substances obtained from cannabis plants varies considerably between plants 
and preparations. The usual mode of administration is by inhalation of combusted 
materials, a practice which carries well known risks to health. 
Two cannabinoid receptors (CB1 & CB2) have been identified to date. CB1 is 
expressed by neurones of the central and peripheral nervous systems and CB2 is 
expressed by immune cells.   The CB1 receptor is widely distributed in the brain, 
with particular concentrations in the hippocampus, cerebellum and hypothalamus. 
Cannabis is associated with a large number of effects including analgesia, anti-
emesis, appetite stimulation, hypothermia and memory and cognitive impairment, in 
addition to the well described euphoria or “high”. There are considerable concerns 
that even modest use of cannabis is associated with an increased long-term risk 
of psychosis and other mental disorders. Evidence suggests that there is a small 
increase in the incidence of psychiatric illness, especially in those who start using 
at a young age, with a genetic predisposition and other risk factors for psychosis. 
There is much stronger evidence that cannabis worsens the prognosis in pre-existing 
psychiatric illness.
The recent advances in the elucidation of cannabinoid pharmacology has provoked 
interest in the development of cannabinoids as analgesics. Clinical trials of plant 
derived cannabinoids have shown analgesic efficacy in multiple sclerosis. However, 
the risk of psychosis is a considerable barrier to the development of such drugs 
for routine clinical use. Nevertheless, a number of drug-development strategies 
which could circumvent the psychosis problems are being actively pursued. The 
immunosupressive effects of CB2 receptor activation should also be borne in mind 
Alcohol
Alcohol acts directly to enhance the effects of the inhibitory peptide gamma amino 
butyric acid (GABA) at the GABAA benzodiazepine receptor. It also has an inhibitory 
effect at the excitatory glutamate NMDA receptor. This produces an additive CNS 
depressant action. There are numerous additional effects, some of which may be 
secondary to the glutamatergic and GABA effects.  It also has direct effects on 5-
HT3 receptors. Desentisation of the GABA system is thought to underlie tolerance 
to alcohol and cross-tolerance with benzodiazepines. Alterations in function are also 
seen in the dopaminergic and serotonergic systems. 
At low doses alcohol induces a sense of disinhibition but at higher doses motor 
and cognitive function become impaired. It is the complexity of alcohol’s action that 
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confounds the otherwise potential use of alcohol as an analgesic or anaesthetic; 
for while it undoubtedly has properties which might be expected to modify pain 
processing, the effects of intoxication are far more prominent.
If alcohol has been consumed heavily and regularly for more than a few weeks, a 
withdrawal syndrome may be observed on cessation of drinking. 
The psychological consequences of alcohol withdrawal include anxiety, panic 
attacks, depression, insomnia, and in more severe cases hallucinations, and 
disorientation and clouded consciousness. Physically the symptoms experienced 
may be restlessness and agitation, tremor and sweating, and raised pulse rate, blood 
pressure, and temperature. In more severe cases withdrawal fits may occur. 
Benzodiazepines
Benzodiazepines augment the actions of the inhibitory CNS neurotransmitter GABA. 
Many but not all patients taking benzodiazepines chronically for medical reasons 
become dependent. However benzodiazepines are also misused recreationally. 
Sometimes their CNS depressant actions are used to counteract the stimulation 
caused by cocaine and amfetamines, but they are also used to intensify the effects 
of other CNS depressant drugs such as opioids, or by themselves, to produce 
relaxant and disinhibitive effects. The available oral dosage forms are commonly 
injected. 
The pattern of benzodiazepine withdrawal is highly variable between individuals. 
Many of the symptoms resemble those of anxiety disorder. Symptoms may include 
anxiety, depressed mood, sleep disturbance, tremor and shakiness, headache, 
and hypersensitivity to touch and pain. The patient may experience perceptual 
disturbances. Epileptic seizures may develop. 
1.4.3 Pharmacological treatment of addicition
Note: For some misused substances such as cannabis and ketamine, there 
are no specific treatments for addiction. For others such as LSD and anabolic 
steroids, a addiction syndrome has proved hard to identify and may not exist. 
For all, the mainstay of treatment is psychological, but may be augmented by the 
pharmacological treatments outlined below (table 1).
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Table 1 Pharmacological treatments for addiction
Misused substance Pharmacological treatments for addiction
Alcohol Acamprosate
Used in the management of alcohol dependence. Its exact pharmacology is unclear. It 
may antagonise glutamate NMDA receptor function, possibly through an effect on AMPA 
receptors. 
Benzodiazepines
Commonly used to medicate the acute phase of alcohol withdrawal. Needs caution 
regarding interaction with other CNS depressant drugs such as opioids or continued alcohol 
consumption.
Disulfiram
Used to deter alcohol use by blocking the inactivation of a major metabolite of alcohol 
(acetaldehyde). Acetaldehyde thus accumulates following alcohol consumption which 
provokes an unpleasant reaction. 
Naltrexone
A long acting opioid antagonist used to help maintain abstinence by reducing the rewarding 
effects (this use is unlicensed in the UK). Opioid blockade with naltrexone must be reversed 
if opioids are needed for pain control.
Anticonvulsants
Carbamazepine is frequently used outside the UK to treat acute alcohol withdrawal.
Thiamine
No alcohol treatment package is complete without vitamin supplementation to reduce the 
risk of Wernicke’s encephalopathy or Korsakoff’s psychosis. This may need to be given 
parenterally.
Benzodiazepines Benzodiazepine substitute prescribing
The long acting diazepam is commonly substituted and then slowly withdrawn. Needs 
caution regarding interaction with other CNS depressant drugs such as opioids and alcohol.
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Opioids Opioid substitute prescribing
The mainstay of drug therapy for opioid addiction is substitution with either methadone or 
buprenorphine. The use of diamorphine as a substitute is currently under review, but is not 
in common use. Initial doses of substitution therapy should be cautious, initiated only with 
laboratory confirmation of continued use, with upward titration until the patient is stable and 
not showing signs of withdrawal. This reduces the risk of accidental overdose and allows 
daily engagement with the patient. The prescribing of CNS depressant analgesics should be 
undertaken with caution in these patients. The partial agonist action of buprenorphine may 
effectively antagonise the analgesic effects of full agonist opioid analgesics.
Lofexidine
Used in acute management of opioid withdrawal. As an α2-noradrenergic agonist its actions 
are to decrease the over-secretion of noradrenaline and so damp down the typical “cold-
turkey” withdrawal symptoms described earlier. Clonidine is a similar drug sometimes still 
used but with more marked hypotensive side effects. 
Naltrexone 
A long acting antagonist at the mu opioid receptor. If taken orally, blockade will last for 
around 72 hours. It is usually used as an aid to abstinence from short acting opioids in 
those who have already passed through the acute phase of withdrawal. Opioid blockade with 
naltrexone must be reversed if opioids are needed for pain control.
Stimulants Stimulant substitute prescribing
Replacement therapy for amfetamine use is not generally available as the risks of abuse, 
inappropriate routes of consumption and diversion are high. Some treatment programmes 
offer prescribed dexamfetamine under close supervision.
Antidepressants 
Occasionally used to treat depression after acute stimulant withdrawal. Interactions may 
occur with medicines prescribed for pain management.
1.4.4 Important drug interactions 
Table 2 identifies some interactions that have been described between prescribed 
medicines used in pain control and common misused substances. The list is not 
exhaustive and omission of a specific combination from this table does not imply 
safety.
Note that some patients with a history of substance misuse will be taking HIV 
medication or medicines for TB. Many of these interact with a wide range of 
other medicines and prescribers should check safety with a pharmacist or Medicines 
Information Centre (contact details inside front cover of BNF) if uncertain.
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Table 2 Pain control and subtance misuse: important drug interactions
Pain Medication Substance of misuse  Effects
Carbamazepine Methadone or buprenor-
phine
Accelerates methadone or buprenorphine metabolism. May 
cause withdrawal and require a dose increase.
NSAIDs or aspirin Alcohol May increase gastrointestinal bleeding.
Opioids Alcohol Additive CNS depressant actions.
Benzodiazepines Additive CNS depressant actions.
Cannabis Use with care. One study suggests cannabis can potentiate CNS 
depressant effects of opioids.
Opioids Prescribed opioids will have additive CNS depressant actions 
with street-derived opioids.
Avoid buprenorphine or nalbuphine as analgesics in patients 
dependent on illicit opioids as it might precipitate withdrawal 
symptoms.
Paracetamol Alcohol Possible association with increased hepatotoxicity in alcoholics.
Phenytoin Alcohol Chronic heavy intake of alcohol may accelerate phenytoin clear-
ance so that bigger doses are needed.
Benzodiazepines Unpredictable. Phenytoin levels may potentially be increased or 
decreased. Benzodiazepine levels tend to decrease.
Methadone or buprenor-
phine
Accelerates methadone or buprenorphine metabolism. May 
cause withdrawal and require a dose increase.
SSRIs Ecstasy and amfetamines Unpredictable. Possibility of additive serotonin effects especially 
with ecstasy giving “serotonin syndrome”. Fluoxetine can also 
inhibit the metabolism of amfetamines causing toxicity. SSRIs 
may blunt ecstasy’s pleasurable effects.
However, SSRIs are often used with MDMA to prolong the 
effects, reduce the severity of the “mid-week blues” and may 
also be neuroprotective. 
LSD May exacerbate “flashbacks” in some individuals. Pleasurable 
effects of LSD may be reduced.
Tricyclic antidepres-
sants
Alcohol Additive CNS depressant actions possible.
Benzodiazepines Additive CNS depressant actions possible.
Cannabis Several case reports of dramatic tachycardia, some requiring 
emergency intervention.
LSD May exacerbate “flashbacks” in some individuals.
Methadone Theoretically may have additive effects on the QT interval and 
cause arrhythmias.
Opioids Additive CNS depressant effect possible.
Valproate Benzodiazepines Valproate may increase benzodiazepine plasma levels giving rise 
to CNS depression.
5HT1 agonists (“trip-
tans”)
Ecstasy and other amfet-
amine derivatives
Possibility of additive serotonin effects giving “serotonin syn-
drome”.
For more information see: 
Wills S Drugs of Abuse (2nd edition) Pharmaceutical Press 2005 ISBN: 0 85369 582 2 
 
Stockley IH Stockley’s Drug Interactions (7th edition) Pharmaceutical Press 2006 ISBN: 0 85369 624 1
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Section 2: Drugs and the Law
2.1 Legal framework 
Drugs that are considered “dangerous or otherwise harmful” to individuals or society are 
controlled and regulated by law. There are three international conventions under which 
most countries (within their own legislative framework) agree to restrict non-medical use of 
and trade in certain classes of drugs (United Nations Office on Drugs and Crime):
• Single Convention on Narcotic Drugs, 1961
• Convention on Psychotropic Substances, 1971
• United Nations Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988
In the UK these drugs are controlled by the Misuse of Drugs Act 1971 (the Act) and 
under the Act drugs are categorized as controlled drugs and their possession, supply 
and production is prohibited unless a person is specifically authorised to do so.  The 
Regulations made under the Act (the Misuse of Drugs Regulations 2001 - as amended) set 
out the conditions governing the conduct of those permitted to possess, prescribe, supply 
or administer controlled drugs.
Many analgesic medications are controlled under the Misuse of Drugs Act 1971 and its 
Regulations.
2.1.1 Misuse of Drugs Act 1971
The purpose of the Misuse of Drugs Act 1971 is to prevent the misuse (non-medical 
use) of those drugs controlled by the Act – controlled drugs (CDs) – by establishing a 
series of criminal offences for their unauthorised, and therefore unlawful, possession, 
possession with intent to supply, supply, importation and unlawful production.
Drugs controlled under the Act are divided into 3 classes. These classes reflect their 
relative harm (to individuals and to society) and the maximum penalties which can 
be imposed in criminal law on persons convicted of any of the offences under the 
Act, in a descending order of severity, from A-C. The maximum penalties for offences 
of possession and supply of the main CDs within each class are outlined below in 
table 3.
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Table 3 Penalties for offences of possession and supply of controlled drugs
Drug Class For Possession For Supply  
Class A – diamorphine (Heroin), Cocaine 
(Crack), MDMA (Ecstasy), lysergic acid diethyl-
amide (LSD), more potent opioid analgesics e.g. 
methadone
Up to 7 years imprisonment or 
an unlimited fine or both
Up to life impris-
onment or an 
unlimited fine or 
both
Class B – amfetamine, barbiturates, less potent 
opioid analgesics e.g. codeine,
Up to five years imprisonment or 
an unlimited fine or both
Up to 14 years 
imprisonment or 
an unlimited fine 
or both
Class C – cannabis, benzodiazepines (and zol-
pidem) ketamine, anabolic steroids, and gamma-
hydroxybutyrate(GHB)
Up to 2 years imprisonment or 
an unlimited fine or both
Up to 14 years 
imprisonment or 
an unlimited fine 
or both
NB: Any Class B drug in injectable form is treated as Class A. Some Class C drugs are legal to possess – for exam-
ple, anabolic steroids are Schedule 4 Part II and may be possessed in medicinal form without a prescription
2.1.2 Misuse of Drugs Regulations 2001 (as amended)
Section 7 of the Act allows for regulations, currently the Misuse of Drugs Regulations 
2001 (the Regulations), to be made that authorize and govern activities, including 
the administration and supply of CDs, otherwise made illegal under the Act. The 
Regulations identify those who may legitimately handle particular drugs, describe the 
circumstances in which CDs may be handled and control the purposes for which a 
particular drug may be supplied. They also regulate where a drug may be produced 
or supplied. It is a criminal offence to breach any of the Regulations.
The Regulations divide CDs into 5 schedules according to the degree to which their 
use is regulated. (The schedules are linked to, but are separate from, the 3 classes 
in which CDs are divided, described above.) Schedule 1 CDs are subject to the 
greatest restrictions and Schedule 5 the least. Restrictions relate to the manufacture, 
supply and possession of CDs, as well as safe custody, prescribing (the form and 
content of prescriptions), dispensing, record keeping, and destruction or disposal. 
It is important to remember that, especially in the case of opioid analgesics, the 
schedule of certain CDs may differ depending on strength, formulation and route of 
administration of the preparation.
Schedule 1 CDs require a Home Office licence, which is generally only available for 
carefully controlled scientific purposes. 
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Sativex is a whole plant medicinal cannabis extract indicated for relief of symptoms 
of multiple sclerosis (MS). Sativex currently remains a Schedule 1 Controlled Drug. 
This means that there are no Misuse of Drugs Act or Regulation requirements on the 
pharmacists to keep records nor on the prescriber to write prescriptions in a form 
other than that required by the Medicines Act ( i.e. a Prescription only Medicine).
The MHRA has issued the manufacturer of Sativex in the UK with a Wholesale 
Dealers Licence and an Importation Licence, for patients with MS. The Home Office 
has therefore been able to issue licences for such supplies and has done so by a 
general licence that covers all doctors who apply on behalf of individual MS patients. 
Dispensing pharmacists are also covered by this licence, which is triggered by an 
application by the doctor to the Home Office Inspectorate.  Supplies can be made 
directly from the company’s domestic stocks.
Examples of drugs contained in the Regulations are as follows:
• Schedule 1: cannabis, ecstasy, LSD
• Schedule 2: includes opioids such as diamorphine, morphine and methadone 
and the major stimulants such as cocaine and amfetamine
• Schedule 3: includes buprenorphine, pentazocine and a small number of minor 
stimulant drugs such as benzphentermine and some benzodiazepines such as 
temazepam and flunitrazepam
• Schedule 4: is subdivided into two parts: Part 1 (CD Benz) contains most of the 
benzodiazepines, zolpidem and ketamine. Part 2 (CD Anab) contains the anabolic 
and androgenic steroids together with 5 polypeptide hormones and clenbuterol.
• Schedule 5: includes preparations of certain CDs, for example codeine, 
dihydrocodeine, morphine that are exempt from full control when present in 
medicinal products of low strength. 
Table 4 sets out a summary of legal requirements for drugs in Schedules 2-5.
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Table 4 Summary of legal requirements for drugs in Schedules 2-5
Schedule 2 Schedule 3 Schedule 4(1) Schedule 4(2) Schedule 5 
Prescription 
Requirements
Yes Yes (except 
Temazepam)
No No No
Handwriting 
Requirements
Repealed except signature
Record in CD Register if 
hold/carry stock
Yes No No No No
Emergency supply 
allowed
No No (except 
phenobarbitone 
for epilepsy)
Yes Yes Yes
Address of prescriber 
must be in UK
Yes Yes No No No
Licence required for 
import/export
Yes Yes Yes Yes unless 
the substance 
is in form 
of medicine 
and for 
administration 
by person to 
himself
No
Period on prescription Up to 30 days 
Good practice 
guidance 
Up to 30 days 
Good practice 
guidance 
Up to 30 days 
Good practice 
guidance 
Up to 30 days 
Good practice 
guidance 
Not specified
Validity of prescriptions 28 days 28 days 28 days 28 days 6 months if 
POM
Repeat prescriptions 
allowed
No No Yes Yes Yes
Private prescriber 
identification number 
required on Private 
prescription
Yes Yes No No No
Private CD Prescription 
to be written only on 
standardized form
Yes Yes No No No
Private CD prescriptions 
forms to be sent to 
relevant agency
Yes Yes No No No
Pharmacist must 
ascertain identity of 
person collecting CD
Yes No No No No
N.B. Some products contained in Schedule 5, such as codeine and dihydrocodeine, are available “over-the-counter” as 
Pharmacy Only [P] medicines.
Adapted by kind permission of the Royal Pharmaceutical Society of Great Britain from Medicines, 
Ethics and Practice: A Guide for Pharmacists and Pharmacy Technicians. Number 30, July 2006
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2.1.3 How to write a Schedule 2 or 3 CD prescription
Following a change in the Misuse of Drugs Regulations in November 2005, it is 
no longer a requirement for a Schedule 2 or 3 CD prescriptions to be handwritten 
– for example, they can now be computer generated or typed - provided that 
the prescriber signs the prescription and the prescription meets the following 
requirements: Please note that the requirements listed below apply to all 
prescriptions, whether or they are written by hand or are computer/machine 
generated. 
The prescription must:
• be in ink or otherwise indelible and be signed by the prescriber;
• be dated (since November 2005 a computer generated date has become 
acceptable);
• except in the case of an NHS or local authority prescription, it must specify 
the address of the person issuing it. NB The Medicines Act requires that all 
prescriptions for prescription only medicines (POMs) contain the prescribers’ 
address;
• specify the name and address of the person for whose treatment it is issued;
• specify the dose to be taken;
• specify, in the case of preparations, the form and where appropriate, the strength 
of the preparation and either the total quantity (in both words and figures) of 
the preparation or the number (in both words and figures) of dosage units, as 
appropriate, to be prescribed must be specified;
• specify the total quantity (in both words and figures) of the CD to be supplied. NB 
The Home Office has expressed the view that a dose of ‘as directed’ or ‘when 
required’ is not acceptable, but ‘one to be taken as directed/or when required’ is 
acceptable;
• in the case of a prescription for a total quantity intended to be dispensed by 
instalments, contain a direction specifying the amount of the instalments which 
may be dispensed and the intervals to be observed when dispensing.
 
A Controlled Drug prescription must not be supplied by any person: 
• unless the prescription complies with the provisions set out above;
• unless the prescriber’s address on the prescription is within the United Kingdom;
• unless the supplier is either acquainted with the prescriber’s signature and has no 
reason to suppose that it is not genuine, or has taken reasonably sufficient steps 
to satisfy his/herself that it is genuine;
• before the date specified on the prescription (It is good practice for the prescriber 
to specify a start date for the prescription – this may not be the same as the date 
of the prescription);
• later than 28 days after the date specified.
The two CDs that are licensed for the treatment of opioid dependence are 
methadone and buprenorphine. The dosage and frequency of dosage used are not 
the same as those used in the treatment of pain. The aim of treatment of addiction 
is the reduction of the opioid withdrawal syndrome and for the majority of patients 
a once a day dosage regimen is adequate to suppress this. However, it needs to 
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be recognised that such a regimen is not adequate for the treatment of pain. A few 
drug misuse patients may be receiving prescriptions for diamorphine, but this is still 
rare. The prescribing of diamorphine for the treatment of addiction is only permissible 
if the prescribing doctor has been issued with a license from the Home Office. This 
differs from the regulations governing the prescribing of diamorphine for pain.
In England the NHS prescription form FP10 (MDA) is used for instalment prescribing 
of CDs by treatment centres and General Practitioners (GPs). A maximum of 14 days 
supply of any Schedule 2 CD, buprenorphine, and diazepam can be prescribed for 
the treatment of addiction using this form. In Wales two types of NHS prescription 
form are used for the treatment of substance misuse by instalment: WP10 (MDA), 
issued by GPs and WP10 (HP) Ad, used principally by drug treatment centres. Up to 
14 days supply of drugs listed in Schedules 2 to 5 of the MDRs will be reimbursed. 
In Scotland, NHS prescription forms HBPB (A) and HBP are issued by drug misuse 
centres and hospitals and can be used to prescribe, in instalments, any drug used in 
the treatment of addiction. GPs may prescribe by instalment on forms GP10. 
The maximum period of treatment allowed on the NHS installment prescription form 
FP10MDA is 14 days
2.2 Emergency prescribing/out of hours supply/prescribing
Emergency prescribing/supply of CDs in the general hospital in the acute medical situation 
is covered by the regulations and protocols relating to CDs.
A more contentious issue is the prescribing/supply out of hours in Accident and Emergency 
Departments (AEDs). It is recommended that patients known by their treating drug service/
prescriber to be likely to present to AEDs have a joint care plan drawn up with the AED. It is 
further recommended that patients presenting with a request for drugs without an identified 
physical need are not prescribed in AED but advised to attend GP or drug services during 
working hours. A protocol regarding the prescribing/supply of controlled drugs in such 
circumstances should be in place and jointly owned by the AED and the Specialist Drug 
Service and known to the staff on the unit.
The addicted patient in pain should not be denied pain control and should be managed as 
the non-addicted patient in assessment of analgesic need. Advice and information should 
be sought from the local Specialist Drug Service or prescribing GP if in Shared Care. 
Corroboration of history can be obtained via urinalysis.
It should be remembered that the addicted patient will have an expectation of immediacy of 
effect of analgesia and therefore will require information and reassurance.
2.3 Non-Medical Prescribing – Current Position on Controlled Drugs
Nurse Independent Prescribers: are currently able to prescribe twelve Controlled Drugs 
independently, including diamorphine, morphine, buprenorphine and fentanyl solely for 
certain specified medical conditions. The specified conditions include transdermal use of 
buprenorphine or fentanyl in palliative care; use of diamorphine or morphine in palliative 
care, for pain relief in respect of suspected myocardial infarction, or for relief of acute or 
severe pain after trauma, including in either case post-operative pain relief.
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Pharmacist Independent prescribers are currently unable to prescribe any Controlled 
Drugs independently (though community pharmacists can sell some Schedule 5 CDs from 
a registered pharmacy)
Both Nurse and Pharmacist Supplementary prescribers can prescribe Controlled 
Drugs under an agreed Clinical Management Plan for a patient in partnership with a doctor.
Patient Group Directions: a number of specified Controlled Drugs can be supplied and/
or administered under a Patient Group Direction in certain specified circumstances. The 
drugs and circumstances are listed in the 2001 Misuse of Drugs Regulations.
Future:  
Joint Medicines Healthcare products Regulatory Agency/Home Office 
Consultations
MLX 336 – Patient Group Directions: This proposes changes to the legislation governing 
the supply of controlled drugs by nurses and pharmacists working under Patient Group 
Directions (PGDs) to allow an expansion of the range of CDs that can be supplied and/
or administered by nurses and pharmacists.  One proposed change is the addition of 
morphine for palliative care pain relief in respect of suspected myocardial infarct.  The 
consultation period for MLX 336 ends on 20 April 2007 with implementation of agreed 
changes anticipated late summer 2007.
Public Consultation – Independent Prescribing of Controlled Drugs by Nurse and 
Pharmacist Independent Prescribers: This consultation seeks views on the proposal to 
expand the range of CDs that can be prescribed by Nurse and Pharmacist Independent 
Prescribers to independently prescribed CDs and, in particular, whether nurse and 
pharmacist independent prescriber should be allowed to prescribe specific Schedule 2 
CDs to addicts for the management of their addiction. The consultation period for these 
proposals finishes on 15 June 2007.
2.4 The Shipman Inquiry - Implications for controlled drug prescribing
The Shipman Inquiry was set up in January 2001, following the conviction of a GP, Harold 
Shipman for the murder of 15 of his patients. The inquiry focused on the methods used by 
Harold Shipman to divert, undetected, large quantities of potentially lethal controlled drugs 
and the reasons it was possible for him to do so for so long without detection. Six Inquiry 
reports were published. The fourth of these, The Regulation of Controlled Drugs in the 
Community, was published on 14 July 2004. The 4th Report addressed the systems for 
ensuring the safe and appropriate use of controlled drugs. The Government’s response to 
the 4th Report, Safer Management of Controlled Drugs was published in December 2004. 
The document endorses the recommendations of the Inquiry that the existing systems for 
management of controlled drugs need to be strengthened to minimize the risks of diversion 
and inappropriate use whilst acknowledging the need to avoid barriers to effective and 
timely care of patients requiring controlled drugs to manage their symptoms. In particular, 
aspects of audit and record keeping, storage and disposal of CDs, prescription writing, 
and patient information have been reviewed and have been or are in the process of being 
updated. 
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Section 3: Clinical Issues
3.1 Current good practice in pain management
3.1.1 Key principles 
It is important to recognize that pain, both acute and chronic, is a complex sensory 
and emotional experience shaped not only by biological but also psychological, 
social and cultural factors and it should be evaluated in this context. Additionally, 
persistent pain has a number of predictable psychosocial consequences which will 
need support and management.
Diagnosis 
Acute pain is usually easy to diagnose and the relationship to tissue damage 
reasonably clear. In the case of persistent pain conditions diagnosis is not always 
possible. A careful assessment is important to evaluate the biomedical, social, and 
psychological contributors to the patient’s presenting complaint.
Factitious disorders are rarely seen amongst those presenting for management of 
persistent pain. However, the likelihood of such disorders being diagnosed in error 
may be more prominent in this group of patients as their complaint is subjective and 
pain is frequently poorly understood by the non-specialist assessor. It is common for 
the significance of investigations (which rarely elucidate the mechanisms of persistent 
pain) to be over-emphasised in comparison to the patient’s account. Further, the 
context of medical encounters, where the patient fears being disbelieved, dismissed, 
and undertreated, affects both patient presentation and clinician judgement, 
mitigating against satisfactory understanding of pain.
Progressive conditions 
In a proportion of patients the underlying disease will be expected to deteriorate, in 
both cancer and non-cancer related conditions.
Non-drug interventions should be considered for all patients. Advice on activity and 
lifestyle should underpin other interventions and the importance of self management 
emphasised. Physical interventions such as Transcutaneous-Electrical Nerve 
Stimulation (TENS) or acupuncture may benefit some patients and have some 
support in the scientific literature. 
Pharmacological interventions should be increased to full therapeutic and tolerated 
doses before switching to a different agent. Pain is a biologically complex 
phenomenon and there is a rationale for combining drugs with different mechanisms 
of action. All treatments need to be individualised to specific patient requirements.
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Psychological dimension
Pain always has a psychological impact, from anxiety about the cause or implications 
to frustration and depression at the limitations on the individual’s usual roles and 
satisfactions. Assessment, formulation and  intervention using cognitive and 
behavioural principles can bring about improvements in pain experience, mood, 
activity level and range (including social involvement and work), and reduced use of 
health care resources. Cognitive behavioural skills and an understanding of pain are 
required to be effective, and this work is usually undertaken by a clinical psychologist 
within a multidisciplinary team, involving particularly medical and nursing personnel 
and physiotherapists.
3.1.2 Opioids in the management of persistent pain: general considerations
Opioids have been shown in clinical trials to be effective analgesics in a number of 
pain conditions. They should be prescribed as part of a rehabilitation plan which may 
include other medical, physical, psychological, social and vocational interventions. 
The pain management plan, with goals, aims, and time scales, should be discussed 
and agreed with the patient (and, where appropriate, his or her carer/s). 
The primary purpose of prescribing opioids is for pain relief but complete relief of 
symptoms is rarely achievable: an acceptable balance between useful reduction in 
pain intensity and side effects is the goal. This balance must be assessed regularly. 
Improvement in physical, psychological and social function are secondary outcomes. 
Good pain relief is marked by improved function in all these domains, and in reduced 
requests for health and social care interventions. Progress towards each of these 
should be monitored.
For pain associated with cancer, use of modified release analgesic preparations 
to provide background analgesia with rapidly acting formulations for breakthrough 
pain is recommended. In the case of persistent non-cancer pain it is usual to use 
sustained release preparations only. Pain intensity fluctuates so an opioid dose 
which provides relief of the most severe symptoms could result in considerable, and 
potentially dangerous overmedication during periods when the pain is less severe. 
Patients with non-cancer pain are encouraged to accept that they will have periods 
of increased symptoms when sustained release opioid preparations are used. 
Opioids are often prescribed in conjunction with other pain relieving drugs and with 
non-pharmacological therapies.There are few data in the literature to support the use 
of particular opioid drugs or preparations for specific pain conditions. The response 
of patients to different drugs remains largely a matter of trial and error. Drugs should 
be tried in a sequential manner, with monitoring of therapeutic effect and adverse 
effects over a period sufficient to allow conclusive comment regarding the efficacy of 
a given preparation for the individual patient.
There should always be discussion of adverse effects of opioids to be balanced 
against benefits. Common adverse effects in particular, sedation, sweating, 
nausea, mood change and constipation should be highlighted. Patients should be 
made aware of potential long term problems including hormonal dysfunction and 
immunosuppression. Symptoms and signs of intoxication and withdrawal from 
opioids should also be discussed. Adverse effects require regular monitoring, and 
where appropriate, the report of a third party (such as a carer) may be sought. When 
a prescription for an opioid is first written, patients may be worried about becoming 
“addicted”. It is good practice to address these concerns and to discuss their 
relevance with the patient, depending upon individual circumstances (see below).
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The plan for opioid use also should include a plan for action in the event of possible 
deviations from the agreed treatment schedule and failure to meet appropriate 
outcomes. 
It is helpful to augment the information given to the patient during the consultation 
with written or taped material to refer to outside consultations.
The plan for opioid use must include brief screening for past or present history of 
substance misuse. This may include urinalysis (with appropriate consent) if there 
is reasonable doubt. The accurate assessment of contemporaneous treatment for 
addiction is mandatory as many of these treatments have important implications for 
the management of pain with opioids (see Table 1). 
When a patient is started on opioids, it is usual for prescriptions to be issued by a 
single practitioner who monitors benefits and adverse effects and adjusts the dose 
accordingly. Close liaison should be maintained with other professionals involved in 
the patient’s care.
3.1.3 Opioid therapy: potential problems
Pain caused by analgesic therapy
• Opioid induced hyperalgesia
There is a potential for development of a hyperalgesic syndrome following 
effective opioid administration. The emergence of increasing pain following opioid 
therapy has usually been assumed to be a phenomenon of pharmacological 
tolerance. However, there are both preclinical and clinical data to support 
the development of a state of abnormal pain sensitivity following opioid 
administration. This may be mediated by:
 central glutamatergic mechanisms
 increase in the synthesis of excitatory neuropeptides such as dynorphin
 descending facilitatory mechanisms arising in the medulla
The relative contributions of these mechanisms may vary between drugs 
and routes of administration. It is not clear to what extent these phenomena 
are important in routine clinical practice but there are important therapeutic 
implications. An opioid-induced pronociceptive state will be worsened by 
increasing opioid dose, whereas a patient who has increased pain as a result of 
tolerance would be expected to improve with further opioid administration.
This pronociceptive state is difficult to diagnose in practice as, unlike hyperalgesic 
syndromes associated with neuropathic pain, it is not associated with allodynia. 
Therefore, someone exposed to opioids long-term either through analgesic 
treatment or use of illicit opioids is likely to be particularly sensitive to at least 
some types of pain.
• Medication overuse headache
Recurring headaches may encourage the frequent use of simple analgesia 
which can develop into a chronic daily habit. Additionally a state of neuronal 
hypersensitivity occurs which is exacerbated by further consuming analgesic 
drugs. The analgesics involved include normal doses of paracetamol, aspirin 
and ibuprofen as well as over-the-counter multi-ingredient preparations. Daily 
administration of triptans and the now rarely used ergotamine can also cause this 
phenomenon. Female migraine sufferers seem to be at particular risk.
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The headache caused by analgesia overuse occurs frequently – at least every 
other day – and can be almost constant in some patients, becoming apparent 
immediately on waking. The pain may be a dull, generalised headache, or a more 
intense pain that occurs between doses as the effects of analgesia wane. 
This problem is eventually rectified if all analgesia is stopped, but this is not easy 
to accomplish since intense ‘rebound’ headaches occur during withdrawal, 
together with sleep and mood disturbances. The most intense phase of 
withdrawal can last ten days or more, but useful symptomatic improvement may 
take several weeks. Patients need support during the process of withdrawal. It 
has been advocated that antidepressants or anticonvulsants, and a short initial 
course of steroids may be helpful, but the published evidence to support these 
interventions is weak.
To minimize the risks of developing analgesia related problems: patients self-
medicating with simple analgesics for recurrent headaches or migraine should be 
advised not to take painkillers every day.
3.1.4 Problem drug use when prescribing controlled drugs for pain
Risk of addiction to prescribed opioids
Although the definition of addiction is well developed, the risk for iatrogenic addiction 
during opioid treatment for pain in patients without a known history of substance 
misuse is variably reported. Retrospective and prospective data are available 
from the literature but the criteria for defining addiction vary considerably between 
reports. If patients require opioids in the long term, dependency may have no 
adverse implications for the individual as long as medication supply and compliance 
continues. The literature suggests that the risk of developing problem drug use is 
somewhat lower when treating cancer pain than when managing pain of non-cancer 
origin. However, cancer patients may be reluctant to admit to substance misuse 
therefore the incidence may be significantly underreported in this population. 
The probability of addiction is likely to be influenced by a number of factors. These 
predictors have not yet been empirically established; however, based on clinical 
experience, they may include the following: 
• Social factors
 Family history of substance misuse
 Substance misusers in social network
 Current victim of abuse
 Occupational risk
• Psychological factors
 Major unresolved emotional issues
  - Abuse
  - Trauma
 Anxiety problems
  - Generalised anxiety
  - Sleep problems
  - Panic
  - Social phobia
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  Personality disorders
  - Dissocial
  - Impulsive
  - Borderline
 Extreme low self-esteem
• Other current or previous substance use/misuse including:
 Benzodiazepines
 Alcohol
Suspecting misuse or addiction to medication
A number of behaviours may be indicative of problem drug use. Most published 
accounts of such behaviours are based on clinical observation but the predictive 
value of these observations in identifying drug misuse has not been validated. 
Behaviours which may cause concern are summarized in table 5.
Table 5  Some examples of worrisome behaviour in patients addicted to prescribed 
drugs 
 
 
• Unsubstantiated report of withdrawal symptoms when further supplies of 
the drug are refused or the dose reduced
• Simulating an exacerbation of the underlying medical condition if a 
prescription is refused or dose reduced
• Giving a history of inefficacy or poor tolerance of alternative medicines 
without misuse potential, or non-pharmacological treatment options
• Asking for prescriptions to be re-issued because of repeated 
unsubstantiated episodes of prescription loss; claiming that supplies have 
run out early; altering the quantity or identity of drugs to be supplied on a 
prescription; approaching a second doctor in order to obtain supplies if the 
first one refuses
• Stealing medication or prescriptions; buying supplies of medication from 
illicit domestic sources, from abroad, or via the Internet
• Making threats, or offering bribes, to prescribers or those supplying 
medication
Diversion
Healthcare professionals have a legal and ethical responsibility to uphold the law and 
to help protect society from drug misuse.  They have a responsibility to prescribe 
controlled substances appropriately, guarding against abuse while ensuring that 
patients have required medication available when they need it. 
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They have a personal responsibility to protect their practice/service from becoming a 
target for drug diversion.
Diversion can include:
• transfer of prescription drugs from intended recipient to others in pain;
• unlawful transfer of prescription drugs from legitimate to illegal channels of 
distribution;
• theft from manufacturers or wholesalers;
• theft from pharmacies, hospitals, surgeries, veterinary practices, care 
homes, hospices;
• “prescription fraud”;
• use of over-the-counter or prescription medicines to synthesise more 
potent drugs with a higher street value;
• use of over-the-counter medicines to augment the effect of prescribed or 
‘street’ drugs i.e. the sedating anti-histamines such as cyclizine, prometha-
zine or dyphenhydramine to produce a ‘buzz’ with methadone.
There are currently no UK data that describe the extent of prescription drug misuse 
in the UK. 
Avoiding opioid medication misuse
Opioid use may escalate gradually. Patients may not see that this may be 
problematic. The patient may be aware that their use of opioid is increasing but be 
afraid to discuss this with their pain team for fear of the prescription being reduced 
or curtailed. A clear explanation to the patient at the outset of the need to be 
aware of an emerging problem will reduce this risk. A relationship of trust between 
prescriber and patient will reassure the patient that developing problems can be 
discussed safely.
If aberrant drug-related behaviour is suspected, the prescriber will need to discuss 
concerns sensitively with the patient. Increasing frequency of clinic visits and 
prescription of small quantities of drug may improve adherence to the agreed 
treatment plan. Clinicians may be asked to provide replacement prescriptions for 
drugs or prescriptions that have been lost or stolen. If there are concerns at the 
start of the treatment plan patients should be advised that lost or stolen drugs or 
prescriptions should be reported to the police and that documentary evidence of 
this should be given to the prescriber. If such loss is recurrent it is reasonable to 
terminate the prescription of opioids.
Aberrant behaviours that appear during therapy must be comprehensively assessed 
and documented. This alerts future prescribers to the potential for problems. If the 
differential diagnosis of addiction is made, the patient can be appropriately referred 
to an addiction specialist for treatment.
3.2 Current good practice in addiction medicine 
Like pain, addiction is a complex phenomenon which can be adequately conceptualised 
only if biological, psychological and social aspects are considered. Labels and 
preconceptions neither explain behaviour nor give useful ways to address it, and are 
therefore unhelpful. 
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Biological aspects of addiction include tolerance, and withdrawal, as previously outlined. 
These are experienced equally in the context of opioid prescribing for pain and in patients 
with addiction problems.
Psychological features of addiction include learnt aspects of behaviour, pleasure seeking, 
and distress avoidance (which can be conceptualised by learning theory). Equally drug use 
can be seen as an attempt to manage aversive emotions, that can stem from a wide variety 
of conditions. 
Social concerns are a vital component when defining substance misuse or addiction. 
In the social context where a drug which induces dependence is available in a secure 
supply, is affordable, and is not sanctioned socially, much of the problematic behaviour 
associated with substance misuse is not observed. Social aspects influencing substance 
misuse include economic factors, deprivation, the social milieu, social exclusion, and the 
experience of reduced opportunities. These problems are usually addressed through social 
interventions. 
Diagnosis
The biological aspects of addiction are also seen in chronic prescribing of opioids 
for pain. The syndrome of pseudoaddiction mimics that of drug seeking behaviour 
in addiction. The management of addiction is in principle very similar to the 
management of chronic pain, and therefore the fine points of diagnosis should take 
second place to adequate assessment of the biological, psychological, and social 
factors involved, and the management of these. 
Non-drug interventions
Adequate social support is important, the interventions should be tailored according 
to the particular needs of the patient, whether the support be referral for financial 
advice, housing advice, or helping with an abusive relationship for example.
Pharmacological interventions
Adequate dosing of replacement opioids is required. With the use of supervised 
consumption large enough doses of Methadone can usually be prescribed to 
achieve stability, without concerns about diversion. When abstinence from illegally 
obtained opioids is achieved, with stabilisation of lifestyle, a planned reduction of the 
prescribed opioid can be instituted. 
Relationships with heathcare professionals
The immediacy of distress reduction experienced by the drug misuser by using their 
drugs of choice, leads them to an expectation that the correct drug will provide rapid 
relief, for example from pain. In addiction they may be experiencing high levels of 
arousal from a number of possible causes which respond quickly to pharmacological 
interventions, but rapidly require escalating doses for the patient with an addiction 
problem to experience the same effect. In this context the expectations of patient 
and pain therapist can be radically different, and the interaction frustrating for both. 
This can lead to the clinician feeling bombarded by the frustrations of the patient, 
and the patient being inadequately treated by the clinician, who has anxieties about 
compounding the addiction problems of his/her patient. 
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It is most helpful for the prescriber to lay out openly the boundaries of the encounter 
with the patient. Thus the prescriber can offer clear advice on what are realistic 
expectations, and what cannot be achieved. Frankness is generally accepted well 
in this patient group, who often perceive professionals as indirect and consequently 
insincere. 
Patients may well have had poor previous experience of interaction with healthcare 
professionals, perhaps related to their own pressing needs for distress relief. 
Tolerance is required from both parties. The clinician may be aware of being beyond 
their knowledge base in dealing with a substance misusing patient and close liaison 
with addiction services is helpful. Appropriate training in addiction management 
for non-specialist clinicians would improve their confidence in supporting and 
understanding of these clinical challenges.
3.2.1 Assessment
Comprehensive assessment of the patient is important and should include specific 
consideration of the following points:
• Does the patient have physical dependence or addiction (see above)? 
Note: Physical dependence is the expected outcome of regular adminis-
tration of certain drugs, in sufficient dosage, over a period of time. It most 
commonly occurs with opioids and benzodiazepines.
• Does a request for increased dose of drug reflect changes in tolerance or 
addiction? Tolerance develops with regular consumption. On withdrawal of 
the drug tolerance is lost rapidly, both to the analgesic and toxic effect.
• If the patient has pain, is the level of analgesia appropriate? Many addicted 
patients receive inadequate levels of analgesia.
• Sensitive assessment of current drug and alcohol consumption and past 
history should be obtained irrespective of site of presentation and treat-
ment. There are no characteristics of the patient with a past or 
current substance misuse problem that are pathognomonic. Some 
features of presentation however, when evaluated within the wider clinical 
picture may alert the prescriber to potential problems. These are summa-
rized in table 6. Urine analysis should be routine to corroborate any history 
of drug misuse/addiction or to identify such if suspected but not declared 
by the patient. If possible this should be carried out before starting treat-
ment.
• The clinician should be aware of barriers to effective assessment. These 
include reluctance or inability of the patient to declare drug use and reluc-
tance or inability of the clinician to assess drug misuse/addiction.
• It is important to determine whether other treating agencies are involved, 
including the patient’s general practitioner.
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Table 6 Features of presentation that may alert practitioner to the possibility of 
substance misuse
• Cutaneous signs of drug abuse - skin tracks and related scars on the 
neck, axilla, groin, neck, forearm, wrist, foot and ankle. Such marks are 
usually multiple, hyper-pigmented and linear. New lesions may be inflamed. 
Shows signs of “pop” scars from subcutaneous injections. 
• Being assertive, aggressive or emotionally labile
• Current intoxication/withdrawal
• May show unusual knowledge of controlled substances.
• Gives medical history with textbook symptoms or gives evasive or vague 
answers to questions regarding medical history.
• Reluctant or unwilling to provide reference information. May have no 
General Practitioner.   
• Will often request a specific controlled drug and is reluctant to try a 
different drug.
• Generally has no interest in diagnosis - fails to keep appointments 
for further diagnostic tests or refuses to see another practitioner for 
consultation;
3.2.2 National Guidelines
A number of national guidelines is available outlining best practice in the 
management of the addicted patient. These include;
Drug Misuse and Dependence - Guidelines on Clinical Management. London 
Department of Health 1999 
Evidence-based guidelines for the pharmacological management of substance 
misuse, addiction and comorbidity: recommendations from the British Association for 
Psychopharmacology. J Psychopharmacol. 2004 ;18(3):293-335.
Models of care for treatment of adult drug misusers. National Treatment Agency for 
Substance Misuse 2002 
The NHS Improvement Plan: Putting people at the heart of public services. London 
Department of Health 2004 
Methadone and Buprenorphine for the Management of Opioid Dependence – NICE 
Technology Appraisal Guidance 114  National Institute for Health and Clinical 
Excellence 2007 http://guidance.nice.org.uk/TA114
None of the above addresses the issue of pain management in the addicted 
patient (with the exception of the management during labour in the pregnant 
addict.) All support full assessment for drug misuse across settings and Drug 
Misuse and Dependence (DH) contains advice on AED management, including the 
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recommendation that ‘doctors should ensure there are clear guidelines available 
to staff to respond to requests for medication (opioid and non-opioid) and injecting 
equipment’. The treatment recommendations in the same document are restricted to 
the management of overdose.
The document Models of care for treatment of adult drug misusers (2002) recognises 
that this population has multiple problems that require effective co-ordination of 
treatment, that several specialist and generic providers may be simultaneously 
involved in the care and treatment, that consistency and parity of approach should 
be ensured nationally and that access to care should be based on individual need 
not historical arrangements. However the physical treatments of this population are 
not addressed.
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Section 4:  Practical solutions
4. 1 Pain control in the addicted patient
4.1.1 Patient needs
There are a number of reasons why individuals who are drug dependent may have 
greater than expected needs regarding pain relief:
• Compared to those who are not dependent, the presence of a drug mis-
use syndrome seems to worsen the experience of pain and individuals may 
have previous experiences of self medication to remove pain and psycho-
logical distress 
• Drug misusers have a low tolerance of non-pharmacological interventions 
to achieve pain control 
• By nature of their chronically relapsing condition, drug misusers have fre-
quent episodes of intoxication, and withdrawal, which may alter the inten-
sity of the pain experience 
• Virtually all forms of addiction are associated with sleep disturbance and 
this is a well established exacerbating factor in chronic pain 
• Depression and anxiety are common features in addiction and these have 
an important influence on the pain experience
• Drug users are more likely to suffer from accidental and non accidental 
injury, and medical complications related to their drug use. This places 
them at high risk from physical problems that may require analgesia.
4.1.2 General guidance 
When a known substance misuser presents with a need for analgesia:
• A full substance misuse and medication history should be taken. This can 
be used to check for drug interactions (see Table 2 and BNF) and to assist 
with choice of an appropriate analgesic. When assessing the impact of 
interactions it is also important to ask about medicines which the patient 
may obtain over the counter, and from complementary medical practitio-
ners or suppliers. It is important to discuss the patient’s use of alcohol as 
this also has specific relevance to the experience of and management of 
pain (see table 7). 
 
The accurate assessment of contemporaneous treatment for addiction is 
also mandatory as many of these treatments have important implications 
for the use of opioid medication (see table 1).
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Table 7 Alcohol and pain: important considerations
• Use of alcohol can increase in response to distress related to chronic pain
• Problems with alcohol intoxication including carelessness with other medi-
cation and accidents
• Alcohol related physical comorbidity
• Interactions between alcohol and other drugs
• Risk of respiratory depression (high risk when alcohol, opioids and benzo-
diazepines used chaotically) 
• Use of alcohol correlates with depression and anxiety compounding dis-
tress from pain
• Alcohol reduces quality of sleep compounding distress from pain
• Pain symptoms must be properly evaluated including relevant investigations and 
taking note of potential contributors to the patient’s current experience of pain.
• If non-pharmacological interventions are known to have utility for the pain 
condition described they should be offered to the patient, with a clear explanation 
of why such interventions are likely to help. Similarly non-opioid medications 
should be used where supported by evidence, again with clear discussion of the 
rationale for any drug used.
• Patients already tolerant to a long-term illicit or prescription opioid taken for 
addiction will derive little analgesic effect from their regular dose. If the patient 
needs opioid analgesia these drugs will have to be prescribed in addition to any 
existing prescribed regimen. For those using illicit opioids, prescribed doses must 
include replacement of the patient’s usual opioid consumption.
• There is little published guidance for management of patients who have chronic 
pain requiring opioid therapy, and who currently exhibit aberrant behaviour 
which may indicate misuse or addiction, or have a history of substance misuse. 
Nevertheless, some general principles may be applied: 
 The therapeutic regimen should be selected with the risk of aberrant 
drug-related behaviours in mind. For example, short-acting opioids (e.g. 
pethidine) are widely acknowledged to have greater abuse potential than 
long-acting or sustained release preparations. Also, non sustained release 
tablets can be more easily crushed and injected. A patient may refuse to 
consider a transition to a sustained–release preparation. Although addiction 
may be a possibility, consider also fear, lack of additional coping strategies 
and true physiologic effect of the drug on the pain, remembering that indi-
vidual patients may respond differently to different opioids.
 The prescriber must communicate clearly with the patient about setting 
reasonable expectations or goals for therapy and about the necessity to 
frequently assess the progress toward these goals. This must include a 
regular review of the prescription.
 The process of building trust between clinician and the patient should 
include a candid discussion of acceptable and unacceptable behaviour. 
The results of such a discussion should be written down and given to the 
patient. This may take the form of a treatment contract although this is not 
required by law.
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 Be aware of the various potential presentations of drug seeking behaviour 
(see tables 5 & 6). Refer patient to, or seek advice from, a pain specialist or 
substance misuse specialist at an early stage where appropriate.
 Treatment decisions need to be made in compliance with pertaining laws 
and regulations.
 Response to treatment including degree of pain control and progress 
towards agreed goals needs to be assessed frequently.
• There are specific considerations for patients receiving methadone, buprenorphine 
or naltrexone. 
Methadone
If an opioid analgesic is appropriate, a non-methadone opioid may be co-
prescribed. It is not necessary to “rationalise” the patient’s entire opioid 
requirements to one drug. 
Buprenorphine
The partial agonist action of this drug (when used as opioid substitution therapy) 
means that it should not be prescribed as an analgesic to patients receiving full 
agonists (e.g. methadone, heroin) as withdrawal may be precipitated. Similarly, 
patients taking high dose buprenorphine as substitution therapy may be relatively 
refractory to opioids prescribed for analgesia.
Naltrexone 
This drug is a long-acting opioid antagonist and patients receiving it as 
therapy for addiction are likely to be refractory to opioid analgesia. In addition, 
administration of opioid antagonists leads to upregulation of opioid receptors with 
a consequent period of opioid sensitivity. When opioid therapy is introduced after 
cessation of naltrexone, careful monitoring will be required. In order to maintain an 
appropriate level of support for the patient, discontinuation of Naltrexone should 
be discussed with their drug worker. In cases where there is an urgent need for 
opioid analgesia this will require continuous infusion to displace naltrexone from 
the opioid receptors. However the patient will require close continuous monitoring 
as, once the naltrexone has been displaced, there is a risk of opioid toxicity from 
the agonist agent. 
• Consultation with others involved in the patient’s care should underpin 
management. It is particularly important that the substance misuse team and the 
patient’s primary care team are kept informed of progress with pain management. 
This is normal good clinical practice, but also supports safe pain management by 
generating accurate information regarding a patient’s current prescribed treatment 
and minimises the risk of a patient seeking medications from more than one 
source.
4.2 Patients recovering from addiction
Prolonged substance misuse leads to permanent change in the neural reward circuitry. This 
gives rise to the potential for reactivation of a substance misuse problem if drugs of misuse 
need to be prescribed for pain control. This results in considerable anxiety for the patient, 
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who may underreport his/her symptoms, and concerns for healthcare professionals who 
may undermedicate pain for fear of inducing relapse. Both anxiety and pain can precipitate 
relapse in this population so it is important to reassure the patient that their pain will be 
adequately treated. It may be necessary to manage anxiety pharmacologically. Patients 
and clinicians need to understand that drug exposure is only one component of relapse 
and that a careful plan for pain management with involvement of appropriate expertise 
can facilitate optimal treatment. The management of acute pain in these patients needs to 
include a clear plan for cessation of therapy and a plan for appropriate support following 
discharge from hospital.
4.3 Common clinical scenarios
The scenarios presented below are quite commonly encountered. There are no right 
answers which apply in all similar situations, but the notes below are offered to guide 
thinking.
I have a patient who I suspect is addicted to her pethidine, which I don’t think that she 
needs. How do I tell? What do I do?
An initial candid, but sensitive, discussion with the patient, airing the prescriber’s concerns 
honestly and allowing the patient to describe hers, may open the door to an attempt at 
gradual withdrawal. Drug withdrawal symptoms should be described and the need for a 
gradual dose reduction emphasized. It is helpful if the patient helps to determine the rate of 
planned withdrawal as this will impart a feeling of control. Alternatively a trial conversion to 
a different opioid might be a basis on which to attempt withdrawal. It is important to ensure 
adequate analgesia or the patient will lose confidence in the process. If the patient indicates 
a willingness to change but is having difficulties adjusting, it may be appropriate to admit 
the patient to hospital.
Some patients will refuse to take an alternative drug and will not accept even a trial 
withdrawal. Ultimately it is usually impossible for prescribers to refuse to continue to 
prescribe analgesia if the patient says it is necessary to control pain. In these situations 
prescribers should be strict about quantities supplied and avoid dose escalation.
Pethidine is a poor choice of analgesic for long term pain control. Its high lipid solubility 
and rapid onset of effect predispose to tolerance and problem drug use. The active 
metabolite of pethidine, norpethidine is neurotoxic and can induce seizures. Pethidine does 
not produce less muscle spasm than equipotent doses of other opioid preparations and 
confers no advantage for the management of visceral pain. This is particularly important in 
the management of conditions such as pancreatitis.
My patient is dependent on oxycodone. How do I wean him off? Should I put him on 
methadone?
If the patient has continuing pain which responds to the drug, the patient and prescriber 
should be reassured that dependence is to be expected and can be managed by 
maintaining supplies and monitoring dose. Dependence becomes problematic if the dose 
needs to be reduced or the drug stopped, in which case withdrawal symptoms may occur. 
These should be discussed with the patient and if they occur despite caution in dose 
tapering, should be actively managed. Towards the end of the dose reduction it may be 
helpful to introduce a weak opioid drug.
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I have a known heroin user needing surgery. He’ll be nil by mouth for three days. What 
analgesia do I use and how do I decide the dose? Should I use IV methadone?
It is not appropriate to use IV methadone as dose equivalence can be difficult to determine. 
There are means of estimating possible oral methadone equivalence to street heroin, but 
these are not always reliable. However, the equivalence of oral to IV methadone is unclear 
because of the variable bioavailability of oral methadone.
For patients taking street heroin, or on maintenance methadone, it is more appropriate 
to manage both potential opioid withdrawal and pain with a conventional opioid such as 
morphine via infusion. Use of a patient controlled device with a constant rate background 
infusion can be helpful. Patients will need to be monitored carefully for pain, opioid 
withdrawal, and overmedication. It is important to involve the hospital acute pain team to 
monitor opioid prescribing and response and to advise on alternative modes of analgesia 
such as local anaesthetic techniques.
I have a patient who I think is shamming pain in order to get analgesia from me. Where do I 
stand ethically if I refuse to supply?
It is important to obtain a substance misuse history for both patient and family and to 
review medical notes available to see if other prescribers have expressed concerns. It is 
helpful to discuss the presentation with other professionals involved in the patient’s care. 
A full pain history including relevant up to date investigations should be documented. In 
accordance with good practice it is reasonable to try non-pharmacological and non-opioid 
therapies initially. 
If there are reasonable grounds for suspicion, discuss problems of long term indiscriminate 
use of opioids with the patient and refer for specialist pain assessment. Drug screening may 
be considered and should also be discussed.
I have a patient who has previously had an opioid addiction, but is now abstinent and 
in recovery. They have chronic non-cancer pain that is proving difficult to manage with 
NSAIDs. Where do I go from here?
It is important to involve both specialist pain and addiction medicine services for this type 
of problem. Non-pharmacological and non-opioid pain management strategies should 
be explored. If opioids are going to be used, psychological support needs to be offered 
to avoid relapse of addictive behaviour. This is more important than the dose of opioids 
used. Modified release preparations with lower abuse potential should be used. Prescribing 
should be monitored carefully and open discussion with the patient maintained.
4.4 Model for relationships between primary care, pain management services, and 
addiction medicine services
4.4.1 General Practice and Pain Management Services 
Good liaison is important when opioids are prescribed for non-cancer pain generally 
and particularly when there may be a possibility of addiction. Initial telephone contact 
between specialist and GP is ideal. Such contact:
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• allows frank discussion of any concerns, and more rapid exchange of infor-
mation
• allows exploration of patient history that may increase suspicion of a ten-
dency to addiction problems
• confirms what the GP is prepared to prescribe
• Allows clear agreement regarding which team member should be the lead 
prescriber
• Facilitates development of an agreed care plan
Ongoing rapid communication is useful. There are a number of advantages to this:
• the patient with an addiction problem may obtain multiple prescriptions 
from different medical sources and prompt information regarding prescrib-
ing information helps to reduce this risk 
• recent changes in medication regimen can be made known to others in the 
healthcare team
• recent life events which may have a bearing on coping strategies can be 
discussed and managed 
Methadone in primary care
Methadone has been used to good effect as an analgesic, and can safely be 
prescribed by GPs. It is particularly beneficial for patients with an addiction problem 
because of its long half-life. Liaison with specialist pain or addiction medicine 
services may be necessary before starting this prescription regimen. It is important 
to remember that methadone is prescribed to be taken only once a day when used 
in the treatment of opioid dependence compared to twice or three times daily when 
used for pain control. 
4.4.2 Liaison with Specialist Addiction Services
There are a significant number of addicts who suffer from chronic pain, and addiction 
develops in a number of chronic pain patients. Particular problems of access to 
services can occur for both these patient groups. Joint working in the form of a 
combined pain and addiction clinic (with medical specialists in pain medicine and 
addiction medicine and support from clinical nurse specialists and CPNs working 
with addiction services) can address the following issues: 
• Patients who have developed an iatrogenic addiction to opioids may, 
understandably, not perceive their problem is one of addiction, and refuse 
to attend for specialist addiction advice. A joint clinic allows these issues to 
be addressed in the first instance. 
• Drug users who experience chronic pain often describe unhelpful experi-
ences of hospital medicine. They drop out of treatment, leaving their chron-
ic pain unevaluated and untreated. Joint working in the form of a shared 
clinic can improve their uptake of pain services, with a consequent lower 
reliance on opioids. 
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• Switching from short-acting to long-acting opioids can result in increased 
patient anxiety because of the expectation of immediacy of effect in this 
client group. Specialist guidance and monitoring from addiction services, 
seen to be closely connected with the pain clinic, can allow these drug 
substitutions to be performed more easily. 
• Where patients require reduction of their opioids, advice to the patient and 
prescriber from addiction medicine specialists can facilitate this process. 
Within these assessment clinics it is important to have access to immediate drug 
screening to aid with decision making in further prescribing. Access to both pain 
clinic and drug workers’ notes is also important, as is close liaison with GPs and 
other people involved in day to day management of the patient. 
The needs of these patients often mean that relatively frequent follow up is required 
with ongoing support in the community. By using existing addiction service 
infrastructure in primary care and linking with pain management expertise it should 
be possible to optimise management of the complex problems with which this 
population present. 
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Section 5:  Special circumstances and populations
5.1 Acute pain management
Patients with a history of substance misuse may need acute pain management in hospital 
following surgery, trauma or other illness. Fear is common amongst these patients who 
expect their pain to be badly managed, anticipate that analgesic medication will be 
withheld and have considerable anxiety related to the possibility of drug withdrawal. It is not 
appropriate to use an acute hospital admission as an opportunity to address the underlying 
substance misuse problem. Any attempt to do so will lead to mistrust, drug seeking 
behaviour and confrontation that quickly becomes difficult to resolve. Careful planning of 
the analgesia provided during this period is essential to avoid this conflict. Early involvement 
of the in-patient pain team is recommended. In the case of patients needing surgery, 
preoperative anaesthetic evaluation and assessment by the acute pain team is mandatory.
The primary objectives during this period are to manage the patient’s pain and avoid the 
consequences of withdrawal. These aims need to be discussed clearly with the patient and 
healthcare staff in order to foster an environment of trust enabling the patient to discuss 
drug use openly in order to inform an effective pain management plan. Reassurances 
regarding confidentiality will assist in developing patient trust. In some hospitals the planned 
analgesic strategy is structured into a more formal contract that the patient agrees to and 
may be asked to sign. Discussion with local specialist drug services is important at this 
stage. The patient may be known to the addiction medicine team who will be able to inform 
the treatment plan, assist in a reliable conversion from street drugs to prescribed analgesics 
and help plan a smooth transition from acute pain intervention to ongoing management of 
the patient’s substance misuse.
It is important to maintain sufficient background medication to avoid withdrawal in addition 
to that needed to provide analgesia. Background opioid requirements can be maintained 
with oral methadone or by opioid infusion with additional analgesia provided by epidural, 
or other appropriate regional technique, or by using intravenous patient controlled opioid 
analgesia (PCA). The PCA will usually need to be at a higher dose than usual, including 
increased size of bolus dose and addition of a background infusion. Careful observation 
and dose titration when setting up the PCA is mandatory to ensure both safety and 
adequacy of pain relief. Epidural analgesia alone, even if containing an opioid in the infusion 
solution will not prevent withdrawal symptoms. The co-administration of paracetamol 
and NSAIDs in a multi modal regimen will improve analgesia and may reduce the amount 
of opioid needed for effective analgesia. It is important to remember that continuing 
management of the patient’s medication on discharge will need support from the local 
drug dependency team and advice from the team needs to be sought when weaning to 
oral analgesia so that this can be planned in parallel with establishing an appropriate opioid 
maintenance regimen.
5.2 Palliative care
The principles of analgesic practice in substance misusers are fundamentally no different 
from those for other adult patients needing palliative care. Substance misuse is a risk factor 
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for other medical conditions and is also a cause and an effect of psychological difficulties 
or psychiatric illness. Substance misusers may present with lung, hepatic or head and 
neck malignancy, vascular disease, neuropathy, ostemyeltis or pancreatitis. They may lack 
organisational skills to follow complex dosing regimes and vary in their ability to attend clinic 
for regular follow-up. Staff concerns about their personal safety are a serious consideration 
when behaviour becomes abusive, and clear boundaries for behaviour require unequivocal 
explanation whilst maintaining a focus on rational therapeutic plans for care.
Addicted patients may receive maintenance therapy from a substance misuse service and 
this should be regarded as a separate prescription from that for analgesia when attending 
as an outpatient. Drug misusers will commonly receive all their medication from inpatient 
units during an admission, but a clear plan for separate follow-ups for substance misuse 
and symptom palliation should be in place on discharge except during the terminal phase 
of an illness. Titration of non-opioid, opioid and adjuvant analgesics should be regulated 
against analgesic response in the usual way; distinctions between symptoms of poor 
analgesic response and withdrawal should be recognised. Symptoms of drug withdrawal 
on inpatient admission are common, and usually occur as a result of cessation of 
recreational drugs.
There are likely to be psychological, social and existential issues influencing pain 
perception and behaviour. When engaging with the patient and carers it is helpful for 
the multidisciplinary team to look beyond the misuse to its causes and implications. It is 
common for there to be resonance between the generations in families and siblings often 
share misusing behaviour; this has implications for bereavement care.
The multidisciplinary team approach to the delivery of palliative care offers realistic hope 
for substance misusers facing the end of life. The context of severe illness and impending 
death provides the opportunity to make meaningful contact with family and carers. Focus 
on important issues in a supportive environment may facilitate acknowledgement and 
sufficient resolution of some of the concerns of this group of patients.
5.3 Pain relief in labour
In practice, intrapartum analgesia for women with a past or current history of substance 
misuse rarely poses problems. As for all women, non-pharmacological options such as 
immersion in water, TENS, mobilisation and relaxation techniques should be encouraged. 
The use of Entonox is also acceptable. Pain relief options should be discussed in the 
antenatal period with a specialist midwife or anaesthetist.
Pregnant women maintained on opioid substitute medications, (methadone or 
buprenorphine) will still require an assessment of their analgesia needs. These women 
will be tolerant to their maintenance dose of methadone or buprenorphine and therefore, 
should still have the option of further analgesia as required. The maintenance (daily) dose of 
methadone or buprenorphine should still be given at a regular time throughout the labour 
period. 
When women request opioid analgesia during labour or following operative or instrumental 
delivery, the standard dose range of opioids (diamorphine, morphine, pethidine and 
fentanyl) should be tried initially. If this provides inadequate, additional doses can be 
carefully administered. 
Following Caesarean or instrumental delivery, usual doses of post-operative opioids 
(intrathecal, epidural or intravenous) can be used although careful additional 
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supplementation may be required. Analgesia should be balanced with paracetamol and a 
non-steroidal anti-inflammatory drug (if not contraindicated).
Women receiving maintenance dosages of the partial agonist buprenorphine will have 
a reduced analgesic benefit from additional opioids. This is a dose-related effect and 
becomes a significant problem at levels above 8mgs of buprenorphine daily. It is advisable 
to avoid supplementing with long acting opioids as further dosages of buprenorphine may 
precipitate opioid withdrawal.
Epidural/intrathecal analgesia with local anaesthetic (or with local anaesthetic in combination 
with an opioid) can provide effective pain relief (during labour, Caesarian Section or 
instrumental delivery) for women receiving opioid substitution therapy.  If analgesia is initially 
ineffective, it is usual to first increase the concentration/dose of local anaesthetic rather than 
the epidural opioid dose.  If further analgesia (in addition to spinally administered drugs) is 
needed following operative delivery, sublingual doses of buprenorphine can be given until 
analgesia is satisfactory if local policy allows for this. This can also be supplemented 
with paracetamol and a non-steroidal anti-inflammatory drug.
Practitioners sometimes worry that systemic opioids in labour may trigger relapse. There 
is no evidence to support this. Appropriate discussion of all options and their relative 
advantages and disadvantages is recommended in the antenatal period.  Additional 
psychological support may be helpful during labour and delivery.
5.4 Pain management and substance misuse in the prison setting
Background
The prevalence of substance misuse is high amongst offenders entering prison. The 1997 
Prison Psychiatric Morbidity study showed that 40% of men and 47% of women on remand 
were severely drug dependant. Current clinical observation suggests that these rates are 
even higher in 2006. Prisoners have a significant physical and psychiatric co morbidly. In a 
study in 1994 of the physical health of male prisoners, 46% of prisoners reported a long-
standing disability or condition, the commonest being musculoskeletal problems.
Those with severe drug dependency suffer from poor health either, directly related to their 
drug habit and also resulting from the low priority that they give to their overall health. Teeth 
and dental hygiene are often affected. Toothache can often be a severe problem when 
substance misuse management is reassessed.
Prisoners with chronic pain are entitled to the same expert assessment of their needs and 
the same pain management as they would expect to receive in the community. 
Assessment
At the time of reception into prison, all prisoners undergo a health screening process. 
This assesses significant health problems, such as drug dependency, physical and mental 
health problems and immediate vulnerability for suicide. At this time all existing treatment 
regimes, including opioid maintenance prescriptions and analgesics, should be confirmed 
with the community prescriber. Those who are drug dependant will be assessed further 
for appropriate needs based treatment, either detoxification or maintenance prescribing, 
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if remanded or on a short sentence, accompanied by a psychosocial interventions. At the 
same time all other co-morbidities will require reassessment.
Pain management 
Acute or chronic pain may occur in patients with a concurrent substance misuse problem 
and may be exacerbated when their substance misuse problems are reassessed in prison. 
Pain can occur when opioid drugs are reduced or as a result of stopping cocaine, crack 
and or alcohol. Such patients may need frequent re-assessment of their pain during this 
period. Reduction in drugs and alcohol, compounded by poor sleep and anxiety can 
exacerbate the pain of a chronic condition. Toothache is a common problem requiring 
urgent referral to the dentist. Advice should be sought on the management of more 
complex cases from a specialist substance misuse doctor and a pain management 
specialist.
Opioid-based analgesics may be subject to misuse in a prison setting. Illicit trading of 
these medications may occur due to the presence of large substance misusing population. 
Bullying may also occur. Prisoners may be coerced into obtaining prescriptions for 
analgesia or if legitimately treated with these drugs, can be bullied into passing them on 
to others. The latter results in the patient receiving inadequate treatment for their pain. 
Inadequate pain management can then lead to increased anxiety and distress and an 
increased risk of self harm. 
A prisoner with chronic pain should have a full assessment and be managed in the same 
way as a patient in the community. This may present problems to the clinician and the 
patient. The responsibility for commissioning health services for prisoners now lies with 
the NHS. If a specialist recommends treatment, or a change of management these needs 
should be discussed with the prison health team so that prison staff , supported by others 
involved in the patient’s care, can try to meet them, This might include attention to the 
patient’s mattress, regular medication, complimentary therapies, antidepressants, aids 
and adaptations. If a prisoner is in high risk category, consideration may have to be given 
to assessing them “in-situ” in the prison. The experience of pain may be exacerbated 
in prison. This may be related to the stress of arrest and imprisonment, and alterations 
in lifestyle including decreased activity and fewer attentionally diverting activities. Simple 
measures invoked at home such as lying in a warm bath, may be restricted in prison and 
other strategies will need to be explored.
It is not uncommon for prisoners to seek opioid-based analgesia for mild or moderately 
painful conditions. Doctors and dentists can by put under considerable pressure by their 
patients to prescribe these types of drugs. 
All prisons should have a prescribing formulary to take account of medication likely to be 
misused, including the possibility of accidental overdose or addiction. Such formularies, 
drawn up in conjunction with local specialists, should include a range of non-opioid based 
medications, with consideration given to the effects when taken in overdose.
Prisoners may also request opioid analgesics when attending hospital. Prison healthcare 
teams should work together with their local hospitals, in particular the Accident and 
Emergency Departments to avoid inappropriate prescribing of these drugs.
Prison Service Order 3550 (Clinical Services for Substance Misusers) requires that 
“administration and consumption of controlled drugs and other drugs subject to misuse 
within a prison setting must be directly observed”. This clearly includes all opioid 
analgesics, and can therefore pose practical problems for those who need their medication 
at frequent intervals, or specific times which are not in keeping with the medication 
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dispensing times of the prison. It may be more appropriate for longer acting preparations 
or transdermal preparations to be prescribed although the use of patches as route of 
administering analgesia is not without risk of diversion in a prison setting. In view of the 
difficulty in ensuring compliance, slow-release oral formulations of opioid analgesics should 
be considered as a viable alternative to transdermal administration. 
Before arrest, a prisoner’s pain may have been managed locally by his/her G.P. and 
possibly a local specialist service. Prisoners when sentenced are frequently moved away 
from the local prison and the prisoner will need to be referred to another specialist team if 
pain continues to be a problem.
The management of pain in the prison setting where substance misuse is a common 
problem is complex. Patients should however be able to achieve a similar degree of 
symptom relief to that which they achieved in the community, although their treatment may 
need some adjustment. Pain management regimens need to be delivered to the individual 
for whom they are intended, in a safe manner, which does not expose the patient, or others 
with whom he/she associates, to unnecessary risk.
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Further Information
Websites
National Institute on Drug Abuse http://www.nida.nih.gov  
US site. The most comprehensive website on substance misuse research, harmful effects and 
patient information.
DrugScope http://www.drugscope.org.uk 
UK site. Similar scope to the above but less comprehensive. Has some good basic introductory 
materials for non-specialists.
Virtual Clearinghouse on Alcohol, Tobacco and Other Drugs 
http://www.atod.org/ 
International site devoted to sharing policies and guidelines on substance misuse from around the 
world.
Daily Dose http://www.dailydose.net 
UK news sevice for substance misuse.
National Treatment Agency UK http://www.nta.nhs.uk/ 
A special health authority, created to improve the availability, capacity and effectiveness of treat-
ment for drug misuse in England.
National Institute on Alcohol Abuse and Alcoholism 
http://www.niaaa.nih.gov 
Comprehensive US site dealing with all aspects of the misuse of alcohol.
Drug Misuse Information Scotland 
http://www.drugmisuse.isdscotland.org/ 
Information, statistics and research on drugs misuse in Scotland.
American Pain Society and American Academy of Pain Medicine. Consensus statement: 
The use of opioids for the treatment of chronic pain. 
American Pain Society Website: 
http://www.ampainsoc.org/advocacy/opioids.htm 
American Academy of Pain Medicine, the American Pain Society and the American 
Academy of Pain Medicine. Consensus statement: Definitions related to the use of opioids for 
the treatment of pain.  
American Pain Society Website:  
http://www.ampainsoc.org/advocacy/opioid2.htm 
The British Pain Society. A consensus statement: Recommended guidelines for pain 
management programmes for adults. 
The British Pain Society website:  
http://www.britishpainsociety.org/pmp_0306_v9.pdf
The British Pain Society. Consensus statement: Recommendations for the appropriate use of 
opioids for persistent non-cancer pain.  
The British Pain Society website:  
http://www.britishpainsociety.org/opioids_doc_2004.pdf  
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